Publications by authors named "Samar B Hasan"
Article Synopsis
- Hidradenitis suppurativa (HS) primarily affects women and individuals of Black and biracial backgrounds, with adalimumab as the only FDA-approved treatment; ongoing trials aim to improve therapeutic options and ensure diverse participations.
- A systematic review of HS clinical trials revealed significant gaps in reporting race and ethnicity, as 31.6% of participants had missing data, with a majority being white (79.3%) and female (72.5%).
- Most studies excluded certain groups such as pediatric patients, pregnant women, and those with varying severity levels of HS, which might hinder treatment equity and access for underrepresented populations.
Background: Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Objectives: To perform a scoping review of pain measurement in randomized control trials (RCTs) of painful skin conditions (PSCs) and use of the pain numerical rating scale (NRS) and visual analogue scale (VAS) in rheumatoid arthritis RCTs, to inform the efforts of HISTORIC to reach consensus on how to measure pain intensity in HS trials.
Methods: A search was conducted on several publication databases.